SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001654954-20-000542
Filing Date
2020-01-16
Accepted
2020-01-16 16:33:29
Documents
1
Group Members
LUMIRA CAPITAL GP, L.P.LUMIRA CAPITAL II (INTERNATIONAL), L.P.LUMIRA CAPITAL II, L.P.LUMIRA GP HOLDINGS CO.LUMIRA GP INC.PETER VAN DER VELDEN

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT edsa_13d.htm SC 13D/A 376020
  Complete submission text file 0001654954-20-000542.txt   377859
Mailing Address 100 SPY COURT MARKHAM A6 L3R 5H6
Business Address 100 SPY COURT MARKHAM A6 L3R 5H6 (905) 475-1234
Edesa Biotech, Inc. (Subject) CIK: 0001540159 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: SC 13D/A | Act: 34 | File No.: 005-87615 | Film No.: 20531355
SIC: 2834 Pharmaceutical Preparations

Mailing Address 141 ADELAIDE STREET WEST SUITE 770 TORONTO A6 M5H 3L5
Business Address 141 ADELAIDE STREET WEST SUITE 770 TORONTO A6 M5H 3L5 416-213-4223
Lumira Capital Investment Management Inc. (Filed by) CIK: 0001702636 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: SC 13D/A